Method development in reversed-phase liquid chromatography (RPLC) can be challenging for structurally similar compounds.
Dr. Bingwen Yan and Dr. Clayton McNeff, ZirChrom Separations, Inc.
Method development in reversed-phase liquid chromatography (RPLC) can be challenging for structurally similar compounds. Validation methods often require a column of orthogonal selectivity be used to ensure no impurities are missed, carbon-clad zirconia phase offers dramatically different chromatographic selectivity when compared to traditional silica-based bonded phases. This note shows selectivity comparison of the zirconia based, carbon-clad ZirChrom® -CARB HPLC column versus a typical silica bonded phase for 22 nonelectrolyte solutes with varying chemical properties.
Method development in RPLC has traditionally been difficult for molecules which are geometric isomers or structurally very similar. In bonded-phase silicas, the partition mechanism responsible for retention in RPLC often does not offer adequate chemical selectivity for such compounds. On the other hand, carbon-based phases provide retention in RPLC through an adsorption mechanism which often increases the chromatographic selectivity for these types of compounds and dramatically increases the chances of resolving pairs of these analytes.
In addition to this enhanced and often orthogonal chromatographic selectivity, carbon-based phases also offer increased chemical and thermal stability of the stationary phase. Zichrom Separations, Inc. has developed ZirChrom®-CARB using zirconia as a stationary phase support, and patented chemical vapor deposition technology to produce a carbon-clad stationary phase suitable for use in reversed-phase liquid chromatography. The graphitized carbon surface is extremely resistant to chemical and thermal attack. The authors have run mobile phases at very high pH (1 M NaOH), very low pH (0.5 M HNO3), and at elevated temperature (200 °C) and have not observed loss of stationary phase. This unique chemistry results in a very selective phase with no detectable bleed by LC–MS.
22 non-electrolyte solutes were injected onto two HPLC columns of equivalent configuration; 1) ZirChrom®-CARB, 3 µm particle size and 2) a leading traditional silica based bonded phase (ODS), 3 µm particle size. For both HPLC columns the k' for each solute was calculated from the resulting data. Each k' was then converted to log k' and graphed, see Figure 1.
Figure 1
Column: ZirChrom®-CARB, 50 mm x 4.6 mm i.d.
(Part Number: ZR01-0546)
Mobile Phase: 40/60 acetonitrile/water
Temperature: 30 °C with Metalox™ 200-C column heater
Flow Rate: 1 mL/min
Injection Vol.: 5 µL
Pressure Drop: 50 bar
Detection: UV at 254 nm
This method can be tailored to your specific application needs. ZirChrom technical support can help to optimize and transfer this method to your site. Please contact ZirChrom technical support at 1-866-STABLE-1 or support@zirchrom.com for details.
ZirChrom phases offer unique selectivity, high efficiency, and excellent chemical and thermal stability.
Visit www.zirchrom.com for more application notes using ultrastable, high efficiency ZirChrom columns.
ZirChrom Separations, Inc.
617 Pierce Street, Anoka, MN 55303
tel. 1-866-STABLE-1
Email: support@zirchrom.com; Website: www.zirchrom.com
Mitigating High Sample Volume Consumption in AAV Aggregate Analysis Using a Biozen™ dSEC-7 by SEC-FL
April 15th 2024This application note showcases a Biozen dSEC-7 SEC chemistry/fluorescence detector solution, offering reliable AAV aggregate analysis in under 10 minutes with as little as 0.5 µL of sample. Across four AAV serotypes, resolution between monomer and aggregates remains consistently high, emphasizing Biozen dSEC-7's efficiency and ability to maintain accurate detection at minimal injection volumes. Ideal for routine testing, this solution ensures precise measurement of a CQA with streamlined sample consumption.
Adeno-Associated Virus (AAV) Serotype Screen Using a Biozen™ dSEC-7 Size Exclusion Column
April 15th 2024With its 700 Å large pore silica particle and hydrophilic diol-type surface chemistry, Biozen dSEC-7 provides excellent resolution of monomer from dimer peaks in under 8 minutes across four different AAV serotypes. This capability is crucial for optimizing gene therapy biopharmaceuticals, ensuring thorough analytical scrutiny to select the most appropriate serotype(s) for enhanced therapeutic outcomes and immunogenic profiles.